John Hamill, the Senior Vice President and Chief Financial Officer of Aprea Therapeutics, Inc. (NASDAQ:APRE), recently acquired 50 shares of the company's common stock. The transaction, which took place on October 11, amounted to a total value of $123, with each share purchased at a price of $2.4638. Following this acquisition, Hamill's total holdings in the company increased to 19,368 shares. The transaction was disclosed in a filing with the Securities and Exchange Commission.
InvestingPro Insights
While John Hamill's recent purchase of Aprea Therapeutics shares demonstrates insider confidence, it's crucial to consider the broader financial context of the company. According to InvestingPro data, Aprea's market capitalization stands at a modest $16.57 million, reflecting its status as a small-cap biotech firm.
InvestingPro Tips highlight that Aprea holds more cash than debt on its balance sheet, which is often seen as a positive indicator for biotech companies still in the development stage. This cash position could provide a buffer for ongoing research and development activities. However, the company is also quickly burning through its cash reserves, a common scenario for pre-revenue biotech firms investing heavily in drug development.
The stock has shown significant volatility, with a notable 19.14% return over the last week, contrasting sharply with a 47.86% decline over the past six months. This volatility aligns with the InvestingPro Tip indicating that Aprea's stock price movements are quite volatile, which is typical for small biotech companies whose fortunes can change rapidly based on clinical trial results or regulatory decisions.
Investors should note that analysts do not anticipate the company will be profitable this year, and Aprea was not profitable over the last twelve months. The company's revenue for the last twelve months as of Q2 2023 was $1.28 million, with a striking revenue growth of 410.91% year-over-year. However, this growth is from a very low base and should be considered in the context of the company's negative gross profit margin of -552.7%.
For those seeking a more comprehensive analysis, InvestingPro offers 11 additional tips for Aprea Therapeutics, providing deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.